Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024)
Innate Pharma's (IPHA) quarterly Cash from Financing Activities came in at -$6.4 million in Q4 2024, down 203.51% YoY from $6.2 million in Q1 2024, and down 37.78% on a QoQ basis from -$4.7 million in Q2 2024.
Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024) Analysis & Trends
Innate Pharma (IPHA) has 6 years of Cash from Financing Activities data on file, last reported at -$6.4 million in Q4 2024.
- Quarterly Cash from Financing Activities fell 203.51% year-over-year to -$6.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$14.6 million (down 128.75% YoY) and the FY2025 annual result came in at $7.1 million, up 210.06% from the prior year.
- Cash from Financing Activities declined to -$6.4 million in Q4 2024, from -$4.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of -$1.0 million in Q2 2022 to a low of -$6.4 million in Q4 2024.
- A 5-year average of -$2.4 million and a median of -$1.5 million in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 30.62% — and 2024, when it slumped 243.43%.
- Tracing IPHA's Cash from Financing Activities over 5 years: stood at -$1.4 million in 2020, then declined by 5.21% to -$1.5 million in 2021, then retreated by 26.32% to -$1.9 million in 2022, then fell by 13.42% to -$2.1 million in 2023, then slumped by 203.51% to -$6.4 million in 2024.
- The last three Cash from Financing Activities figures came in at -$6.4 million (Q4 2024), -$4.7 million (Q2 2024), and -$2.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2024 | -6.42 Mn |
| Jun 30, 2024 | -4.66 Mn |
| Jun 30, 2024 | -4.66 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2019 | -867,449.38 |
| Jun 30, 2019 | -867,449.38 |